glp-1 and dual glp-1/gip receptor agonists This review summarizes how GIP/GLP-1 act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based Comparison of GLP-1R Mono-Agonist vs.
Description
2021;106:e592e601
Semaglutide is entering phase 3 evaluation in patients with early AD (NCT04777396)
Prevalence of maternal obesity at delivery and association with maternal and neonatal outcomes
GLP-1RA therapy was initially developed to treat type 2 diabetes
doi: 10.3389/fendo.2018.00649 Received 19 June 2018 Accepted 15 October 2018 Published 06 November 2018 Volume 9 - 2018 Edited by Marco Falasca, Curtin University, Australia Reviewed by Marta Letizia Hribal, Universit degli studi Magna Grcia di Catanzaro, Italy
Glucagon-like Peptide 1 receptor activation inhibits microglial pyroptosis via promoting mitophagy to alleviate depression-like behaviors in diabetic mice
